CN112649522A - Method for detecting related substances vinblastic acid and apovincamine acid in injection - Google Patents
Method for detecting related substances vinblastic acid and apovincamine acid in injection Download PDFInfo
- Publication number
- CN112649522A CN112649522A CN202011368498.9A CN202011368498A CN112649522A CN 112649522 A CN112649522 A CN 112649522A CN 202011368498 A CN202011368498 A CN 202011368498A CN 112649522 A CN112649522 A CN 112649522A
- Authority
- CN
- China
- Prior art keywords
- acid
- impurity
- vinpocetine
- apovincamine
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
Abstract
The invention provides a method for detecting related substances, namely vinblastine and apovincamine acid, in an injection, quantitative identification is carried out on impurity, namely vinblastine and apovincamine acid, in the vinpocetine injection by adopting a high performance liquid chromatography, and the chromatographic conditions are as follows: the filler of the chromatographic column is cyano silane bonded silica gel, the flow rate is 0.5-0.7 mL/min < -1 >, the column temperature is 30-34 ℃, and triethylamine solution and ethanol which are 0.1-0.25 mol/L and have the volume ratio of 30-65: 65-70 are used as mobile phases. The method utilizes the high performance liquid chromatography to measure the content of the impurity vincamine acid and the impurity apovincamine acid in the vinpocetine injection, has the advantages of good separation effect, sensitivity, accuracy and the like, and ensures the quality stability, uniformity and curative effect of the product; the method is simple, has strong specificity and good reproducibility, effectively ensures the quality and the curative effect of the vinpocetine injection and has strong practicability.
Description
Technical Field
The invention relates to the field of medicine quality detection, in particular to a method for detecting related substances, namely vinblastic acid and apovincamine acid in injection.
Background
Vinpocetine (vinpocetin, abbreviated as VIN) has the chemical name: ethyl (13aS,13bS) -13 a-ethyl-2, 3,5,6,13a,13 b-hexahydro-1H-indole [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylic acid.
The product is firstly researched and developed by Cedeon Richter, Hungarian medicine company in 1978 to be marketed, and is mainly used for treating cardiovascular and cerebrovascular diseases, ischemic hypertensive encephalopathy, cerebral arteriosclerosis, cerebral ischemia, intermittent cerebral blood flow insufficiency, cerebral vasospasm, cerebral thrombosis, and brain diseases caused by aging.
The chemical structure of the product is as follows:
referring to related varieties in Chinese pharmacopoeia 2015 edition, referring to the quality standard, adopting a high performance liquid chromatography, and adopting an isocratic elution mode, wherein the known impurities calculate the content of the known impurities by peak area according to an external standard method, the unknown impurities measure the content of the unknown impurities of the product according to a main component self-contrast method, and meanwhile, as researches on synthesis starting materials, synthesis intermediates and inquired related impurities are added, the methodology research on related substances is carried out again on the basis of the detection method of the related substances in the original declared standard, and the research on the related substances methodology finds that the vinpocetine synthesized intermediate, namely vinpocetine, and the apovincamine acid, which is the impurity, cannot be separated in the original detection method of the related substances, so that a detection method is urgently needed to solve the problems.
Disclosure of Invention
In view of the above, the invention provides a method for detecting related substances, namely vinpocetine and apovincamine acid, in the injection, and the method is simple, has good separation degree, strong specificity and good repeatability, effectively ensures the quality and the curative effect of the vinpocetine injection, and has strong practicability.
The technical scheme of the invention is realized as follows:
a method for detecting related substances, namely vinblastine acid and apovincamine acid in injection adopts high performance liquid chromatography to quantitatively identify impurity, namely vinblastine acid and impurity, apovincamine acid in the vinpocetine injection, and the chromatographic conditions are as follows: the filler of the chromatographic column is cyano silane bonded silica gel, the flow rate is 0.5-0.7 mL/min < -1 >, the column temperature is 30-34 ℃, and triethylamine solution and ethanol which are 0.1-0.25 mol/L and have the volume ratio of 30-65: 65-70 are used as mobile phases.
Further, the preparation method of the detection solution comprises the following steps:
(1) preparing a test solution:
taking a vinpocetine injection sample, and taking a mobile phase as a diluent to prepare a test solution, wherein each 1ml of the test solution contains 0.8-1.2mg of vinpocetine, and the preferential concentration is 1.0 mg;
(2) impurity control solution:
taking the reference substance of impurity vincamine acid and impurity apovincamine acid, and taking mobile phase as diluent to prepare reference substance solution of impurity, wherein each 1ml contains 1.6-2.4 μ g of vincamine acid and 1.6-2.4 μ g of apovincamine acid, preferably 2.0 μ g;
(3) system applicability test solution:
taking a vinpocetine reference substance, and taking the impurity reference substance solution in the step (2) as a diluent to prepare a system applicability test solution, wherein each 1ml of the system applicability test solution contains 0.8-1.2mg of vinpocetine, and the preferential concentration is 1.0 mg.
Further, the chromatographic column is an ECOSIL CN chromatographic column.
Further, the specification of the chromatographic column is 4.6mm × 250mm, 5 μm.
Further, the detection wavelength is 280 nm.
Furthermore, the sample injection amount is 15-20 mu L.
Further, the flow rate was 0.6 mL. min-1.
Compared with the prior art, the invention has the beneficial effects that:
(1) the method utilizes the high performance liquid chromatography, adopts the combination of the specific formula flow and the specific chromatographic condition to determine the contents of the impurity vincamine acid and the impurity apovincamine acid in the vinpocetine injection, has the advantages of good separation effect, sensitivity, accuracy and the like, and ensures the quality stability, the uniformity and the curative effect of the product;
(2) the quality control method of the invention is simple, has strong specificity and good reproducibility, effectively ensures the quality and the curative effect of the vinpocetine injection and has strong practicability.
Drawings
FIG. 1 is a high performance liquid chromatogram (scan) of the reference substance of vinblastine impurity and apovincamine acid impurity in the content determination of vinpocetine injection;
FIG. 2 is a high performance liquid chromatogram (scan) of the sample containing vinblastic acid impurity and apovincamine acid impurity in the content determination of vinpocetine injection;
FIG. 3 is a linear relationship between the peak area and the concentration of vincamine acid;
FIG. 4 is a linear relationship between apovincamine acid area and concentration.
Detailed Description
In order to better understand the technical content of the invention, specific examples are provided below to further illustrate the invention.
The experimental methods used in the examples of the present invention are all conventional methods unless otherwise specified.
The materials, reagents and the like used in the examples of the present invention can be obtained commercially without specific description.
The vinpocetine injection adopted by the invention is produced by Hainan cucurbita doll pharmaceutical industry group limited company.
Example 1
(I) determination of impurity vincamine acid and impurity apovincamine acid
(1) Precisely measuring a proper amount of vinpocetine injection, and quantitatively diluting the vinpocetine injection by using a mobile phase to prepare a solution containing 1.0mg of vinpocetine in each 1ml serving as a test solution;
(2) taking appropriate amount of each of the impurity vincamine acid and the impurity apovincamine acid as reference substances, precisely weighing, adding mobile phase for dissolving, and quantitatively diluting to obtain mixed solution containing 2 μ g of each of the impurity vincamine acid and the impurity apovincamine acid per 1ml as reference substance solution;
(3) taking 10mg of a vinpocetine reference substance, putting the vinpocetine reference substance into a 10ml measuring flask, dissolving the vinpocetine reference substance by using an impurity reference substance solution, diluting the vinpocetine reference substance to a scale, and shaking up the vinpocetine reference substance to be used as a system applicability test solution;
(4) and (3) injecting 20 mu l of system applicability test solution into a liquid chromatograph, recording a chromatogram, and sequentially obtaining an impurity VIII peak, an impurity IX peak and a vinpocetine peak, wherein the separation degrees among the peaks meet the requirement.
(5) And (3) absorbing the reference solution and the test solution, respectively injecting the reference solution and the test solution into a liquid chromatograph for determination, wherein if a chromatographic peak with the retention time consistent with that of the peak VIII and the peak IX of the impurity exists in the chromatogram of the test solution, the peak area of the chromatographic peak is calculated according to an external standard method, and the vincamine acid and the apovincamine acid have no more than 0.2% of the labeled amount.
The chromatographic conditions are as follows: the filler of the chromatographic column is cyano silane bonded silica gel (ECOSIL CN, 4.6mm multiplied by 250mm, 5 μm), the flow rate is 0.6mL min < -1 >, the column temperature is 30 ℃, the detection wavelength is 280nm, the sample injection amount is 20 μ L, and 0.25mol/L triethylamine solution and ethanol with the volume ratio of 35: 65 are used as mobile phases.
The high performance liquid chromatogram of the impurity vincamine acid and the impurity apovincamine acid reference substance in the content determination of the vinpocetine injection is shown in figure 1;
the high performance liquid chromatogram of the sample containing the impurity vincamine acid and the impurity apovincamine acid in the content determination of the vinpocetine injection is shown in figure 2.
In the step (one), the HPLC is examined for the following specific analysis:
1. linear relation
The test results show that, as shown in FIG. 3-4, the peak area and the concentration of the apovincamine acid are in a good linear relationship within the concentration range of 0.554-8.861 μ g/ml, and the peak area and the concentration of the apovincamine acid are in a good linear relationship within the concentration range of 0.441-7.056 μ g/ml.
2. Specificity
The peak of the degradation product and the main peak in each destructive test can be effectively separated, no degradation impurity is generated in the blank of the auxiliary material, and the measurement of related substances is not interfered. Under each damage condition, the vinpocetine injection originally developed and marketed sample and the developed sample material reach conservation and balance. The similarity of the peak purity of the main peak in each destructive test is more than 0.999, which indicates that the main peak is a single substance peak, and the specificity of the detection method is good.
Example 2-this example differs from example 1 in that a 0.25mol/L triethylamine solution and ethanol in a volume ratio of 30: 70 are used as mobile phases. The results show that the peak shapes of vinpocetine, vincamine acid and apovincamine acid are good.
Example 3-this example differs from example 1 in that a 0.1mol/L triethylamine solution and ethanol in a volume ratio of 1: 1 are used as mobile phases. The results show that the peak shapes of vinpocetine, vincamine acid and apovincamine acid are good.
Example 4-this example differs from example 1 in that the column temperature is 34 ℃. The results show that the peak shapes of vinpocetine, vincamine acid and apovincamine acid are good.
Example 5-this example differs from example 1 in that the flow rate was 0.5mL min-1. The results show that the peak shapes of vinpocetine, vincamine acid and apovincamine acid are good.
Example 6-this example differs from example 1 in that the flow rate was 0.7mL min-1. The results show that the peak shapes of vinpocetine, vincamine acid and apovincamine acid are good.
Comparative example 1-this comparative example differs from example 1 in that the column was replaced with an exform C18 column. The results show that the vincamine acid peak and the apovincamine acid peak interfere with each other.
Comparative example 2-this comparative example differs from example 1 in that the flow rate was 1mL min-1, and the results showed that the vincamine acid peak and apovincamine acid peak interfere with each other.
Comparative example 3-this comparative example differs from example 1 in that the column temperature was 28 ℃, and the results show that the vincamine acid peak and apovincamine acid peak interfere with each other.
Comparative example 4-this comparative example differs from example 1 in that a 0.2mol/L ammonium acetate solution and acetonitrile in a volume ratio of 40:60 are used as mobile phases. The results show that the vincamine acid peak and the apovincamine acid peak interfere with each other.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (8)
1. A method for detecting related substances, namely vinblastine acid and apovincamine acid in injection is characterized in that high performance liquid chromatography is adopted to quantitatively identify impurity, namely vinblastine acid and impurity, apovincamine acid in the vinpocetine injection, and the chromatographic conditions are as follows: the filler of the chromatographic column is cyano silane bonded silica gel, the flow rate is 0.5-0.7 mL/min < -1 >, the column temperature is 30-34 ℃, and triethylamine solution and ethanol which are 0.1-0.25 mol/L and have the volume ratio of 30-65: 65-70 are used as mobile phases.
2. The method for controlling the quality of vinblastine and apovincamine as impurities in vinpocetine injection as claimed in claim 1, wherein the detection solution is prepared by the following steps:
(1) preparing a test solution:
taking a vinpocetine injection sample, and taking a mobile phase as a diluent to prepare a test solution, wherein each 1ml of the test solution contains 0.8-1.2mg of vinpocetine.
(2) Impurity control solution:
taking the reference substance of impurity vincamine acid and impurity apovincamine acid, and taking mobile phase as diluent to prepare reference substance solution of impurity, wherein each 1ml contains 1.6-2.4 μ g of vincamine acid and 1.6-2.4 μ g of apovincamine acid;
(3) system applicability test solution:
taking a vinpocetine reference substance, and taking the impurity reference substance solution in the step (2) as a diluent to prepare a system applicability test solution, wherein each 1ml of the system applicability test solution contains 0.8-1.2mg of vinpocetine.
3. The method as claimed in claim 1, wherein the chromatography column is ECOSIL CN chromatography column.
4. The method as claimed in claim 1, wherein the chromatographic column is 4.6mm x 250mm, 5 μm.
5. The method for detecting related substances vinblastine and apovincamine acid in injection as claimed in claim 1, wherein the sample volume is 15-20 μ L.
6. The method as claimed in claim 1, wherein the flow rate is 0.6 mL-min-1.
7. The method as claimed in claim 1, wherein the detection wavelength is 280 nm.
8. The method for controlling the quality of vinblastine and apovincamine as impurities in vinpocetine injection as claimed in claim 2, wherein the detection solution is prepared by the following steps:
(1) preparing a test solution:
taking a vinpocetine injection sample, and taking a mobile phase as a diluent to prepare a test solution, wherein 1.0mg of vinpocetine is contained in each 1ml of the test solution.
(2) Impurity control solution:
taking the reference substance of impurity vincamine acid and impurity apovincamine acid, and taking mobile phase as diluent to prepare impurity reference substance solution, wherein each 1ml contains 2.0 μ g of vincamine acid and 2.0 μ g of apovincamine acid respectively;
(3) system applicability test solution:
and (3) taking a vinpocetine reference substance, and preparing a system applicability test solution by taking the impurity reference substance solution obtained in the step (2) as a diluent, wherein each 1ml of the vinpocetine reference substance contains 1.0mg of vinpocetine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011368498.9A CN112649522B (en) | 2020-11-30 | 2020-11-30 | Method for detecting related substances vinblastic acid and apovincamine acid in injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011368498.9A CN112649522B (en) | 2020-11-30 | 2020-11-30 | Method for detecting related substances vinblastic acid and apovincamine acid in injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112649522A true CN112649522A (en) | 2021-04-13 |
| CN112649522B CN112649522B (en) | 2022-02-22 |
Family
ID=75349575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011368498.9A Active CN112649522B (en) | 2020-11-30 | 2020-11-30 | Method for detecting related substances vinblastic acid and apovincamine acid in injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112649522B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE885723A (en) * | 1979-10-15 | 1981-04-15 | Richter Gedeon Vegyeszet | NOVEL HALOGEN-APOVINCAMINIC ACID ESTERS PROCESS FOR THEIR PREPARATION AND MEDICINAL PREPARATIONS CONTAINING THEM |
| US4344950A (en) * | 1979-02-11 | 1982-08-17 | Richter Gedeon Vegyeszeti Gyar Rt. | Parenteral solvent and a process for the preparation of stable solutions containing same |
| CN1200733A (en) * | 1995-11-29 | 1998-12-02 | 日高弘义 | Apovincaminic acid derivative and medicine contg. same |
| CN102952128A (en) * | 2012-10-30 | 2013-03-06 | 河南中帅医药科技发展有限公司 | Refining method of vinpocetine |
| CN103288822A (en) * | 2013-06-09 | 2013-09-11 | 北京澳合药物研究院有限公司 | Preparation method of vinpocetine |
| CN104165942A (en) * | 2014-07-30 | 2014-11-26 | 东北制药集团股份有限公司 | Method for detecting content of vinpocetine compound |
| CN110455944A (en) * | 2019-07-31 | 2019-11-15 | 武汉华龙生物制药有限公司 | Method that is a kind of while detecting apo- Changchun amino acid and Changchun amino acid in vinpocetine |
-
2020
- 2020-11-30 CN CN202011368498.9A patent/CN112649522B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4344950A (en) * | 1979-02-11 | 1982-08-17 | Richter Gedeon Vegyeszeti Gyar Rt. | Parenteral solvent and a process for the preparation of stable solutions containing same |
| BE885723A (en) * | 1979-10-15 | 1981-04-15 | Richter Gedeon Vegyeszet | NOVEL HALOGEN-APOVINCAMINIC ACID ESTERS PROCESS FOR THEIR PREPARATION AND MEDICINAL PREPARATIONS CONTAINING THEM |
| CN1200733A (en) * | 1995-11-29 | 1998-12-02 | 日高弘义 | Apovincaminic acid derivative and medicine contg. same |
| CN102952128A (en) * | 2012-10-30 | 2013-03-06 | 河南中帅医药科技发展有限公司 | Refining method of vinpocetine |
| CN103288822A (en) * | 2013-06-09 | 2013-09-11 | 北京澳合药物研究院有限公司 | Preparation method of vinpocetine |
| CN104165942A (en) * | 2014-07-30 | 2014-11-26 | 东北制药集团股份有限公司 | Method for detecting content of vinpocetine compound |
| CN110455944A (en) * | 2019-07-31 | 2019-11-15 | 武汉华龙生物制药有限公司 | Method that is a kind of while detecting apo- Changchun amino acid and Changchun amino acid in vinpocetine |
Non-Patent Citations (6)
| Title |
|---|
| G. SZEPESF 等: "Normal-Phase Dynamic (Solvent-Generated) Molecular Complexation Chromatography Using Anionic Ion Exchangers", 《JOUMAL OF CHROMATOGRAPHY》 * |
| NOUMAN MUHAMMA 等: "Kinetics and Mechanisms of Vinpocetine Degradation in Aqueous Solutions", 《JOURNAL OF PHARMACEUTICAL SCIENCES 》 * |
| 伍丽萍等: "LC-MS/MS测定人血浆中长春西汀体内代谢物阿朴长春胺酸 ", 《中国药学杂志》 * |
| 张小娟等: "RP-HPLC测定长春西汀冻干乳剂的含量及其有关物质 ", 《军事医学科学院院刊》 * |
| 李锐: "高效液相色谱法同时测定长春西汀3种中间体杂质残留", 《现代化工》 * |
| 王翰斌 等: "HPLC 法测定长春西汀注射液中阿朴长春胺酸和长春胺酸的研究", 《中国保健营养》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112649522B (en) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104965041A (en) | High performance liquid chromatography detection method for parecoxib sodium isomer | |
| CN115453012B (en) | Reversed-phase HPLC method for simultaneously measuring multiple positional isomers in voathixetine hydrobromide | |
| CN108445098B (en) | Analysis method for detecting impurities in vitamin A palmitate | |
| CN112649522B (en) | Method for detecting related substances vinblastic acid and apovincamine acid in injection | |
| CN110261508B (en) | Analysis method of related substances in amiodarone hydrochloride raw material medicine | |
| CN107589197B (en) | Method for separating and determining isoxofenac and related substances thereof by HPLC (high performance liquid chromatography) method | |
| CN114428134B (en) | Method for detecting brivaracetam intermediate isomer | |
| CN113030328B (en) | Method for detecting genotoxic impurities in ivabradine hydrochloride | |
| CN110412164B (en) | Method for detecting related substances of mexiletine hydrochloride | |
| CN111812240B (en) | Separation method and application of oxytocin and three impurities | |
| CN114324703A (en) | Method for simultaneously detecting multiple amino acids | |
| CN109765316B (en) | Method for detecting levetiracetam from medicine | |
| CN113848271A (en) | Method for detecting related substances in levocetirizine hydrochloride oral solution | |
| CN114942280A (en) | Method for content determination and mass spectrum confirmation of 12 hair dyes in cosmetics | |
| CN114280191A (en) | Method for detecting related substances in bis-cysteine and preparation thereof | |
| CN114216972A (en) | Method for measuring content of dipalmitoyl hydroxyproline | |
| CN115248260A (en) | HPLC analysis detection method for related substances in cisatracurium besilate bulk drug | |
| CN111983109A (en) | Chiral analysis method of alkaloid in tobacco or tobacco product | |
| CN113125587A (en) | Tofacitinib intermediate and detection method of enantiomer thereof | |
| CN113419006B (en) | Liquid phase analysis method of aprepitant optical isomer | |
| CN113777180B (en) | Method for simultaneously detecting sitafloxacin and various isomer impurities thereof | |
| CN114965723B (en) | Detection method of 2-acylaminothiazole compounds | |
| CN115097026B (en) | Method for detecting pyrazolopyrimidine benzenesulfonate compounds from medicines | |
| CN102565203B (en) | Method for separating and determining methyhaaltrexone bromide and impurities thereof with liquid chromatography | |
| CN115856141A (en) | Method for separating and determining tinib key intermediate and related impurities thereof by HPLC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |